Phaseline

Companies › AVEO Pharmaceuticals

AVEO Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Other, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ficlatuzumab (AV-299)
Hepatocyte growth factor inhibitor
HGFPhase 3Metastatic Head-and-neck Squamous-cell CarcinomaAug 2027
AV-380
anti-GDF-15 monoclonal antibody
GDF15Phase 1CachexiaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05865535AV-380Phase 1CachexiaOtherDec 2026
NCT06064877Ficlatuzumab (AV-299)Phase 3Metastatic Head-and-neck Squamous-cell CarcinomaOncologyAug 2027

From the company's SEC filings

Complete response letters from FDA

Targets

GDF15 (1) HGF (1)

Companies with the same targets

CatalYm Kexing Biopharm Pfizer Claris Biotherapeutics Kringle Pharma

Companies built like this

Celltrion CatalYm Samsung Bioepis Orca Biosystems Grit Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.